Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Boehringer Ingelheim. (1/24/19). "Press Release: Boehringer Ingelheim Partners with AMPATH to Scale Up Knowledge, Skills and Training for Healthcare Providers in Kenya". Ingelheim.

Region Region Kenya
Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 AMPATH Consortium
Products Product healthcare
  Product 2 diagnostic services
     


> Partnership with AMPATH aims to advance Boehringer Ingelheim’s Healthcare Initiative In Reach Africa

> Collaboration partnership to build a holistic and sustainable health system in Kenya


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, and the AMPATH Consortium recently announced their partnership to enable better healthcare access and expertise for local communities and healthcare providers in Kenya. Special focus will be given to developing community-based strategies, geared towards enhancing local skillsets and expertise among medical personnel, improving referral mechanisms and services, and increasing access to essential diabetes and hypertension medication.

Boehringer Ingelheim will primarily support AMPATH’s programs with funding, in-kind support, and expertise as part of its In Reach Africa initiative. “With the aim of enabling vital healthcare access, imparting invaluable skills to the local workforce and also improving referral process, we will work closely in partnership with the AMPATH team to support their ability to improve the quality of care offered to patients,” said Ayman Eissa, Head of Human Pharma – Sub-Saharan Africa at Boehringer Ingelheim.

In the foreground is AMPATH’s integrated cardiovascular disease (CVD) management program, which focuses on community screening for diabetes and hypertension, with those testing positive referred to a health center. Boehringer Ingelheim will support with the training of healthcare workers, the acquisition of basic diagnostic devices such as glucometers, blood pressure machines, weighing scales, and appropriate tools for monitoring and evaluation.

Healthcare providers will be equipped with knowledge and skills to manage hypertension and diabetes. In addition, a care program at all levels of the health care system will be implemented so that care is targeted and available depending on the severity of the disease.

“Helping people means so much more than medical treatment. It’s only when we combine care with nutrition and family support, education, counseling, health insurance, food and income security, and self-sufficiency that we truly change lives for the better,” said Dr Jeremiah Laktabai, Head of Population Services at AMPATH. “At the community level, we will focus on screening and linking patients with hypertension and diabetes to providing adequate care. At the lowest level health facilities, we will support nurses with training, mentorship, and referral guidelines. With increased screening efforts using various community-based strategies, we will increase access to care through both group- and facility-based care, and finally increase access to essential medications for diabetes and hypertension through strengthening the existing supply chain mechanisms, and using innovations such as our revolving fund pharmacies.”

Improving referral mechanisms and services will also be a key component of ensuring a care system that links primary and specialty chronic disease services. Cardiovascular disease represents an important complication of uncontrolled diabetes and hypertension that is now the leading cause of non-communicable disease deaths globally.

In Kenya, hypertension treatment and control rates have been reported as suboptimal. For example, in a cross-sectional study looking at prevalence, treatment and control of hypertension among type 2 diabetic patients at a referral hospital, good blood pressure control was observed in only 40% of patients. As of 2017, it was estimated that there were 458.900 reported cases of diabetes in Kenya, set to rise even further to 498,000 cases by the year 20301. This makes it all the more imperative to put comprehensive healthcare protocols in place, which will be aided as a result of the new partnership between Boehringer Ingelheim and the AMPATH Consortium. In another population-based cross-sectional survey of two slums in Nairobi, only 20% of patients who had diabetes were aware of their condition and fewer than 5% of patients had their blood glucose under control2. Therefore, early diagnosis and linkage to care are important cornerstones of successful management of chronic illnesses and prevention of acute complications.


1https://www.diabetes.co.uk/global-diabetes/diabetes-in-africa.html (link is external)
2https://www.ncbi.nlm.nih.gov/pubmed/24118454 (link is external)


Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.


Further Media Channels:
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim (link is external)
www.pinterest.com/biglobal


AMPATH

AMPATH is a partnership between Moi University, Moi Teaching and Referral Hospital, North American universities led by Indiana University, and the Kenyan Government. The consortium works together to exchange knowledge, share resources, train medical professionals, and reach patients and whole communities.


Media Contact

Maria Isabel Rodriguez Fernandez
Media + PR
Phone +49 6132 77 143007
Mobile +49 151 150 26111
Fax +49 6132 77 6601
› E-mail

Binger Straße 173
55216 Ingelheim am Rhein
GERMANY

   
Record changed: 2019-02-03

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top